{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:48:10Z","timestamp":1793303290080,"version":"4.5.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011345","name":"Academy of Military Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Propranolol (Prop), a classic non-selective \u03b2-adrenergic receptor antagonist, has long played a significant role in the treatment of cardiovascular diseases such as hypertension and arrhythmias. Compared with its peripheral regulatory effects, the potential therapeutic value of Prop in neurological disorders such as post-traumatic stress disorder (PTSD), memory dysfunction, autism spectrum disorder (ASD), anxiety, migraine prophylaxis, and essential tremor is gradually being re-evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review aims to integrate the latest evidence from clinical and preclinical studies, systematically reviewing the effects of Prop on neurological diseases and its potential mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Specifically, we explore its translational value from the perspective of \u03b2-adrenergic receptor subtype-specific regulation, thereby assessing its potential for precision medicine in neurology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Finally, this review outlines novel therapeutic strategies targeting \u03b2 receptors for treating central nervous system (CNS) diseases, with the ultimate goal of providing a robust theoretical foundation and clear translational pathways for future drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1752025","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:23:18Z","timestamp":1786958598000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potential of propranolol in central nervous system disorders"],"prefix":"10.3389","volume":"17","author":[{"given":"Jia-Ning","family":"Zhao","sequence":"first","affiliation":[{"name":"School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, China"]},{"name":"Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, China"]},{"name":"Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yu","family":"Yin","sequence":"additional","affiliation":[{"name":"Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/608430","article-title":"Molecular imaging in traditional Chinese medicine therapy for neurological diseases","volume":"2013","author":"Wang","year":"2013","journal-title":"BioMed Res Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1287867","article-title":"Organ failure: central nervous system","volume":"32","author":"Naval","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2021.04.004","article-title":"Inflammatory diseases of the central nervous system","volume":"39","author":"Malani Shukla","year":"2021","journal-title":"Neurol Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101452","article-title":"Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases","volume":"37","author":"Wildner","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jhep.2024.12.017","article-title":"Carvedilol vs. prop for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis","volume":"83","author":"Fortea","year":"2025","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.30723\/ijp.v13i26.284","article-title":"Prop","volume":"42","author":"Al-Majed","year":"2017","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(70)90403-5","article-title":"Prop as an antihypertensive agent","volume":"79","author":"Prichard","year":"1970","journal-title":"Am Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198900131-00004","article-title":"Pathophysiology of prop in hypertension","volume":"70","author":"Frohlich","year":"1977","journal-title":"South Med J"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1139\/y86-247","article-title":"Nonstereoselective aspects of prop pharmacodynamics","volume":"64","author":"Alkondon","year":"1986","journal-title":"Can J Physiol Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-198704000-00007","article-title":"Lack of sleep-inducing properties of prop (80 mg) in chronic insomniacs previously treated by common hypnotic medications","volume":"2","author":"Danjou","year":"1987","journal-title":"Int Clin Psychopharmacol"},{"key":"B11","article-title":"Beta 1 receptors","volume-title":"Statpearls","author":"Alhayek","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198400282-00002","article-title":"Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation","volume":"28","author":"Molinoff","year":"1984","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-017-1349-4","article-title":"Stimulation of \u03b2(1)- and \u03b2(2)-adrenoceptors dilates retinal blood vessels in rats","volume":"390","author":"Mori","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15704","article-title":"BDNF promoted osteoblast migration and fracture healing by up-regulating integrin \u03b21 via TrkB-mediated ERK1\/2 and AKT signalling","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2007.07.002","article-title":"Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses","volume":"117","author":"Brodde","year":"2008","journal-title":"Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106664","article-title":"Suppression of neuronal AMPK\u03b22 isoform impairs recognition memory and synaptic plasticity","volume":"201","author":"Swift","year":"2024","journal-title":"Neurobiol Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"E344","DOI":"10.1152\/ajpendo.00418.2016","article-title":"CNS \u03b2(3)-adrenergic receptor activation regulates feeding behavior, white fat browning, and body weight","volume":"313","author":"Richard","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11481-024-10150-w","article-title":"MFG-E8 ameliorates nerve injury-induced neuropathic pain by regulating microglial polarization and neuroinflammation via integrin \u03b23\/SOCS3\/STAT3 pathway in mice","volume":"19","author":"Zhang","year":"2024","journal-title":"J Neuroimmune Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291717000708","article-title":"Posttraumatic stress disorder associated with unexpected death of a loved one: Cross-national findings from the world mental health surveys","volume":"34","author":"Atwoli","year":"2017","journal-title":"Depress Anxiety"},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1037\/a0031474","article-title":"Meta-analysis of dropout in treatments for posttraumatic stress disorder","volume":"81","author":"Imel","year":"2013","journal-title":"J Consult Clin Psychol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1874467214666210525160944","article-title":"A review on post-traumatic stress disorder (PTSD): Symptoms, therapies and recent case studies","volume":"15","author":"Thakur","year":"2022","journal-title":"Curr Mol Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_463","article-title":"Memory reconsolidation","volume":"37","author":"Haubrich","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.717956","article-title":"The mechanisms and boundary conditions of drug memory reconsolidation","volume":"15","author":"Chen","year":"2021","journal-title":"Front Neurosci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pneurobio.2012.07.002","article-title":"Reconsolidation of memory: a decade of debate","volume":"99","author":"Besnard","year":"2012","journal-title":"Prog Neurobiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/070674371405900408","article-title":"Trauma reactivation plus prop is associated with durably low physiological responding during subsequent script-driven traumatic imagery","volume":"59","author":"Brunet","year":"2014","journal-title":"Can J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.307","article-title":"Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation","volume":"37","author":"Soeter","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.03.045","article-title":"Effects of Prop on the modification of trauma memory reconsolidation in PTSD patients: A systematic review and meta-analysis","volume":"150","author":"Raut","year":"2022","journal-title":"J Psychiatr Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17050481","article-title":"Reduction of PTSD symptoms with pre-reactivation prop therapy: a randomized controlled trial","volume":"175","author":"Brunet","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161044","article-title":"Modification of fear memory by pharmacological and behavioural interventions during reconsolidation","volume":"11","author":"Thome","year":"2016","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2025.102571","article-title":"Psychiatric comorbidity in children and adolescents with ADHD: A systematic review and meta-analysis","volume":"118","author":"Njardvik","year":"2025","journal-title":"Clin Psychol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s10194-024-01923-y","article-title":"Migraine and cognitive dysfunction: a narrative review","volume":"25","author":"Fernandes","year":"2024","journal-title":"J Headache Pain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/geronb\/gbaa040","article-title":"State of the science on mild cognitive impairment (MCI)","volume":"24","author":"Anderson","year":"2019","journal-title":"CNS Spectr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.120111","article-title":"Prop's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis","volume":"38","author":"Lonergan","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.19-15-06623.1999","article-title":"Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors","volume":"19","author":"Przybyslawski","year":"1999","journal-title":"J Neurosci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1056\/nejmra012941","article-title":"Post-traumatic stress disorder","volume":"1","author":"Yehuda","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nlm.2018.01.010","article-title":"Prop disrupts consolidation of emotional memory in Lymnaea","volume":"149","author":"Shymansky","year":"2018","journal-title":"Neurobiol Learn Mem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2003.10.001","article-title":"A systemically administered beta-adrenoceptor antagonist blocks corticosterone-induced impairment of contextual memory retrieval in rats","volume":"81","author":"Roozendaal","year":"2004","journal-title":"Neurobiol Learn Mem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2006.12.013","article-title":"Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats","volume":"32","author":"Aisa","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.06.047","article-title":"Prop restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model","volume":"64","author":"Dobarro","year":"2013","journal-title":"Neuropharmacology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2015.10.023","article-title":"Pregnancy-related anxiety: a concept analysis","volume":"55","author":"Bayrampour","year":"2016","journal-title":"Int J Nurs Stud"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710099","article-title":"Prop versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder","volume":"23","author":"Szeleszczuk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.1974.tb00269.x","article-title":"Prop, anxiety and the central nervous system","volume":"1","author":"Granville-Grossman","year":"1974","journal-title":"Br J Clin Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115612236","article-title":"Prop for the treatment of anxiety disorders: Systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/s1121189x00001421","article-title":"The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys","volume":"18","author":"Kessler","year":"2009","journal-title":"Epidemiol Psichiatr Soc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(66)91863-0","article-title":"The effect of prop on anxiety","volume":"1","author":"Granville-Grossman","year":"1966","journal-title":"Lancet"},{"key":"B46","article-title":"Comparative efficacy of prop, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial","volume":"48","author":"Meibach","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(65)92340-8","article-title":"Effect of adrenergic receptor blockade of the tachycardia of thyrotoxicosis and anxiety state","volume":"2","author":"Turner","year":"1965","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.49.10.1212","article-title":"Physiological response to Prop and diazepam in chronic anxiety","volume":"1","author":"Tyrer","year":"1974","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21621","article-title":"Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation","volume":"67","author":"Saito","year":"2013","journal-title":"Synapse"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.919831","article-title":"Prop administration modulates neural activity in the hippocampal hilus during fear retrieval","volume":"16","author":"Leal Santos","year":"2022","journal-title":"Front Behav Neurosci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-072220-021440","article-title":"Major depression and its recurrences: Life course matters","volume":"18","author":"Monroe","year":"2022","journal-title":"Annu Rev Clin Psychol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.134892","article-title":"Protective effect of Prop and nadolol on social defeat-induced behavioral impairments in rats","volume":"725","author":"Zaidi","year":"2020","journal-title":"Neurosci Lett"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.05.054","article-title":"Frequency of utilization of beta blockers in patients with heart failure and depression and their effect on mortality","volume":"124","author":"Kim","year":"2019","journal-title":"Am J Cardiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.12740\/pp\/onlinefirst\/192685","article-title":"The association between beta-blockers use and depression - narrative review","volume":"59","author":"Tokarczyk","year":"2025","journal-title":"Psychiatr Pol"},{"key":"B55","article-title":"Prop-induced depression and psychosis","volume":"4","author":"Parker","year":"1985","journal-title":"Clin Pharm"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0073","article-title":"Does acute Prop treatment prevent posttraumatic stress disorder, anxiety, and depression in children with burns","volume":"28","author":"Rosenberg","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1037\/e584762012-144","article-title":"Autism spectrum disorder","volume":"392","author":"Lord","year":"2018","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291718002283","article-title":"Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis","volume":"49","author":"Hollocks","year":"2019","journal-title":"Psychol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00213-023-06452-1","article-title":"Randomized controlled trial of prop on social communication and anxiety in children and young adults with autism spectrum disorder","volume":"241","author":"Beversdorf","year":"2024","journal-title":"Psychopharmacol (Berl)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4199-0","article-title":"Effects of Prop on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study","volume":"233","author":"Zamzow","year":"2016","journal-title":"Psychopharmacol (Berl)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1017\/s1355617712000070","article-title":"Noradrenergic moderation of working memory impairments in adults with autism spectrum disorder","volume":"18","author":"Bodner","year":"2012","journal-title":"J Int Neuropsychol Soc"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00050-2","article-title":"Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan","volume":"14","author":"Ecker","year":"2015","journal-title":"Lancet Neurol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10548-021-00831-7","article-title":"Functional networks abnormalities in autism spectrum disorder: age-related hypo and hyper connectivity","volume":"34","author":"Haghighat","year":"2021","journal-title":"Brain Topogr"},{"key":"B64","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1362361319868633","article-title":"Beta-adrenergic antagonism alters functional connectivity during associative processing in a preliminary study of individuals with and without autism","volume":"24","author":"Hegarty","year":"2020","journal-title":"Autism"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-010-9098-8","article-title":"Effect of Prop on functional connectivity in autism spectrum disorder--a pilot study","volume":"4","author":"Narayanan","year":"2010","journal-title":"Brain Imaging Behav"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118756245","article-title":"Prop for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders","volume":"32","author":"Sagar-Ouriaghli","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","article-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","volume-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects","author":"Kouli","year":"2018"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression","volume":"132","author":"Riederer","year":"2025","journal-title":"J Neural Transm (Vienna)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106543","article-title":"Design, synthesis and evaluation of monoketene compounds as novel potential parkinson's disease agents by suppressing ER stress via AKT","volume":"136","author":"Chen","year":"2023","journal-title":"Bioorg Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.46.6.1548","article-title":"Improvement of levodopa-induced dyskinesia by prop in parkinson's disease","volume":"46","author":"Carpentier","year":"1996","journal-title":"Neurology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510x(71)90183-3","article-title":"Combined treatment of parkinsonian tremor with prop and levodopa","volume":"14","author":"Abramsky","year":"1971","journal-title":"J Neurol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann Neurol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann Neurol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.5414\/cp203559","article-title":"The association between antihypertensive therapy and the incidence of Parkinson's disease in patients followed in general practices in Germany","volume":"57","author":"Warda","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00736-2","article-title":"\u03b2-adrenoceptor drugs and parkinson's disease: a nationwide nested case-control study","volume":"34","author":"de Germay","year":"2020","journal-title":"CNS Drugs"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa012","article-title":"\u03b2 2-agonists and the incidence of parkinson disease","volume":"189","author":"Giorgianni","year":"2020","journal-title":"Am J Epidemiol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of parkinson's disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov Disord"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007694","article-title":"Use of \u03b22-adrenoreceptor agonist and antagonist drugs and risk of parkinson disease","volume":"93","author":"Hopfner","year":"2019","journal-title":"Neurology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28085","article-title":"Beta agonists and progression of parkinson's disease in older adults: a retrospective cohort study","volume":"35","author":"Marras","year":"2020","journal-title":"Mov Disord"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70140","article-title":"Association between \u03b2-adrenoreceptor agonists and antagonists and Parkinson's disease: Systematic review and meta-analysis","volume":"34","author":"Szmigiel","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B83","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jad.2015.11.051","article-title":"Prop's impact on cognitive performance in post-traumatic stress disorder","volume":"192","author":"Mahabir","year":"2016","journal-title":"J Affect Disord"},{"key":"B84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/15622970601187784","article-title":"Blood pressure is associated with cognitive impairment in young hypertensives","volume":"9","author":"Gupta","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/children10101639","article-title":"A pilot feasibility study assessing the combined effects of early behavioral intervention and prop on autism spectrum disorder (ASD)","volume":"10","author":"Hirst","year":"2023","journal-title":"Children (Basel)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.01.24311354","article-title":"Prop reduces Parkinson's tremor and inhibits tremor-related activity in the motor cortex: A placebo-controlled crossover trial","volume":"97","author":"van der Heide","year":"2025","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1752025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:23:20Z","timestamp":1786958600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1752025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":86,"alternative-id":["10.3389\/fpsyt.2026.1752025"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1752025","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1752025"}}